Breathe Well Live Well
|
Teva's injectable asthma biologic approved by FDA
The Pharmaceutical Journal The biologic treatment, which is given as a four-weekly infusion alongside other drugs, is indicated to help those patients with severe asthma who still have serious asthma attacks despite being on regular medication. It is expected to be launched in … |
View full post on asthma – Google News
|
GSK's First Biologic Treatment For Asthma – Nucala Holds Multi-Billion Dollar Potential
Seeking Alpha Nucala was recently approved by the USFDA and EMA for the treatment of patients with severe Asthma of eosinophilic phenotype. In the base case, Nucala should reach peak sales of $2b. If Nucala is approved in other indications (COPD, HES) too, it can … |
View full post on asthma – Google News
|
First-in-class biologic maintenance therapy approved for severe asthma
ModernMedicine Nucala, developed by GlaxoSmithKline, is an interleukin-5 (IL-5) antagonist monoclonal antibody that reduces the production and survival of esosinophils, which are one of the inflammatory cell types involved in asthma. The biologic is to be … |
View full post on asthma – Google News
MedPage Today |
Biologic Eases Subset of Severe Asthma
MedPage Today For severe eosinophilic asthma, the novel monoclonal antibody mepolizumab cut exacerbations whether given as an injection or infusion and reduced steroid use in patients dependent on them, two trials showed. The drug, which targets interleukin-5 (IL-5 … A respiratory expert undermines GSK's case for new asthma drug mepolizumab Glaxo asthma drug successful in clinical trials (GSK) GSK reports positive Phase III results of its mepolizumab in asthma |
View full post on asthma – Google News
CTV News |
Novel Biologic Promising for Allergic Asthma
MedPage Today SAN DIEGO — A novel first-in-class biologic agent targeting allergic inflammation appeared promising for allergen-induced asthma in a phase IIb trial. AMG 157, an anti-thymic stromal lymphopoietin (TSLP) humanized monoclonal antibody, reduced most … Researchers discover new potential antibody treatment for asthma Canadian study finds potential antibody treatment for mild asthma Hamilton researchers discover potential asthma treatment |
View full post on asthma – Google News
The Pharma Letter |
Biologic May Tame Severe Asthma
MedPage Today A. A. Take Posttest. SAN DIEGO — Lebrikizumab, a novel monoclonal antibody against the inflammatory cytokine IL-13, might have reduced exacerbations in severe asthma in a randomized trial, although manufacturing problems undermined any conclusions. Roche drug cuts asthma attacks, improves lung function -study Roche scores upbeat data for a personalized asthma drug with blockbuster hopes AAAAI 2014: Roche's lebrikizumab shows reduction of asthma attack rates |
View full post on asthma – Google News
|
Gene findings suggest biologic asthma–obesity link
medwireNews The team identified several genes associated with chronic inflammation in asthma that are more highly expressed in obese individuals than those at a healthy weight. And, in morbidly obese patients with Type 2 diabetes, weight loss following gastric … |
View full post on asthma – Google News